
Pallas Health Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.1/10
Best for: the most complete public disclosure of pharmacies and prescribing physicians we have found
Pallas Health scores highest on state availability and ease of access.
Semaglutide
then $199/mo ongoing
Tirzepatide
then $299/mo ongoing
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Not disclosed
Coaching
Not disclosed
No insurance needed · Vetted by our editors
Pallas Health is a telehealth platform operated by Brentmoor, Inc. offering compounded semaglutide and tirzepatide alongside brand-name Wegovy, Ozempic, Zepbound and Mounjaro. Compounded plans average $199 and $299 a month with provider care, check-ins and messaging included and no separate membership fee, and the price stays the same at every dose. Its clinical disclosures page is unusually complete: two named advising physicians with verifiable NPIs, the clinical partner Lion MD, six named partner pharmacies, and coverage in all 50 states plus DC.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Pallas Health at a glance
- Type
- GLP-1 telehealth provider
- Starting price
- $139/mo
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- Availability
- All 50 states
- FDA status
- No FDA warning letter on record
How we scored Pallas Health
Each dimension is scored algorithmically from Pallas Health’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
7.6/10At $199/mo, Pallas Health runs about 17% above the $170 median for GLP-1 providers, and the first month drops to $139. Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
8.5/10Pallas Health offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.8/10Online intake and platform experience — consult included in the price; 8 platform features disclosed.
Trust & Safety15%
9.0/10Key details fully confirmed by our editors; no FDA warning letters on file; discloses which pharmacy makes its medication.
Accessibility10%
9.1/10Pallas Health treats patients in all 50 states. FSA/HSA cards are accepted.
Support10%
6.3/10Pallas Health provides standard clinician follow-up; no extended coaching or community program is disclosed.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this Pallas Health review
Last checked August 2026- Confirmed current pricing across 2 dose/plan tiers
- Confirmed availability in all 50 states
- Confirmed what the monthly price does and doesn't include
- Verified the compounding pharmacy partner and its accreditation
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: high.
What we checked
- Provider's own pricing page
- $199–$299/mo across 2 dose/plan tiers — checked September 2026
- State pharmacy licensing & LegitScript status
- compounding partner licensed in 1 state
- FDA warning-letter register
- No letter on file for this provider
- Compounding pharmacy partners
- Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub, Foothills Pharmacy
What to expect when you sign up with Pallas Health
We walked Pallas Health’s public signup flow in August 2026 to document the process — the steps, pricing transparency, and what’s required — before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Read the public pricing, which states the first-month and 12-week figures for both drugs before any account
- 2Start a visit and complete an online intake; medication ships only when a clinician prescribes
- 3A Lion MD clinician licensed in your state reviews the intake, plus a synchronous video visit where state law requires one
- 4For plans purchased on or after 8 September 2026 checkout saves your payment method and charges nothing; the $60 video-state deposit applies only to older plans
- 5On approval the balance is charged and the subscription begins, anchored to the approval date
- Both the first-month price and the recurring 12-week charge are published on the homepage and the GLP-1 treatment page.
- The clinical disclosures page names the provider network, both advising physicians with NPIs, all six partner pharmacies and the states served.
- Pallas cites Massachusetts, Rhode Island and Vermont telemedicine rules as the reason it publishes clinician information publicly.
- Under the charge-on-approval checkout you are not charged the full amount until a clinician approves; a declined plan refunds the deposit in full.
- The homepage "200,000+ patients" figure is hard to reconcile with the clinical page's reference to a July 2026 launch and waitlist patients.
- The video-visit states are now enumerated: Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and D.C., with the other 43 states fully asynchronous.
- Plan terms are sold as 4, 12, 24 or 48 weeks; the 48-week term is charged in full when the prescription is issued.
Pallas Health customer support
- Phone
- +1 (440) 601-3717
- Hours
- Mon-Fri 9am-5pm ET
GLP-1 medications Pallas Health offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
Peptides Pallas Health offers
Beyond GLP-1s, Pallas Health also offers these peptides — tap any for our evidence-based guide.
Pricing
Prices re-verified
$139 for the first month, then $597 every 12 weeks, which Pallas advertises as a $199/mo average. A 48-week term is advertised at a $159/mo average, charged in full on prescription. Same price at every dose.
$179 for the first month, then $897 every 12 weeks, advertised as a $299/mo average. A 48-week term is advertised at a $259/mo average, charged in full on prescription. Same price at every dose.
Ready to get started?
Plans and promotions change often — check Pallas Health's current pricing and active discounts before you decide.
Pallas Health compounding-pharmacy partners
Each partner below is a 503A or 503B pharmacy that Pallas Health routes prescriptions through.
Strive Pharmacy
Epiq Scripts
Casa Pharma Rx
The Pharmacy Hub
- License footprint
- 1 states: FL
Foothills Pharmacy
What we like
- Names six partner pharmacies with phone numbers and websites, the most complete pharmacy disclosure we have recorded.
- Publishes two advising physicians with NPI numbers you can look up yourself in the federal NPPES lookup.
- Price stays the same at every dose, and provider care, check-ins and messaging are included with no membership fee.
- Offers brand-name Wegovy, Ozempic, Zepbound and Mounjaro alongside compounded options, and serves all 50 states plus DC.
Watch-outs
- Billed $597 every 12 weeks, not monthly; at 4.33 cycles a year the true cost is about $216/mo, above the $199 advertised.
- The homepage claims "200,000+ patients" while the clinical page describes a July 2026 launch and existing waitlist patients.
- The current cycle is not prorated or refunded once a clinician has issued the prescription.
- A live video visit is required in Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and D.C.
Pallas Health: one all-in price, billed every 12 weeks
Pallas Health sells compounded semaglutide and tirzepatide at a price that does not move when your dose does, and it also dispenses brand-name Wegovy, Zepbound, Ozempic and Mounjaro for cash. The homepage leads with “First month from $139.” That number is real. What the banner doesn't say is that the standing plan is not billed monthly at all: after the first month, a compounded plan renews every 12 weeks, and the monthly figure Pallas advertises is an average of that charge.
How the pricing actually works — and the catch
Compounded semaglutide is $139 for the first month. After that, Pallas charges three months' worth in a single payment every 12 weeks, which it advertises as a $199 monthly average. Tirzepatide has the same shape: $179 for the first month, then a 12-week charge that averages $299 a month. Both figures are all-in. Pallas's own wording is “Provider visits, follow-ups and messaging included — no membership fee,” and shipping is free on every plan.
Two things to keep in mind. A 12-week cycle comes around 4.33 times a year, not four, so over a calendar year the quarterly plan costs about eight percent more than the advertised average suggests. A 48-week annual plan lowers the average on both drugs by roughly forty dollars a month, but you pay the whole term at once. Against a category median of about $170, the quarterly semaglutide plan sits above the middle. The consult, the check-ins and the shipping are already inside that number.
Nothing is charged at checkout. Since September 2026, Pallas saves your card and charges only once a clinician prescribes; if the clinician declines, you pay nothing. Once a prescription is issued, though, the order is final and “the current cycle isn't prorated or refunded” from then on. There is a separate “6-month promise” as well. Stay on a paid plan for six continuous months and log your doses, check-ins and weights. If you're then unhappy, or lost no net weight, you can ask within 30 days for those six months of plan payments back. One claim per patient.
Medications and the dose ladder
The compounded plans are weekly injections of semaglutide or tirzepatide, and the flat price holds at every step: “your compounded plan costs the same at every dose.” Pallas does not publish a compounded dose ladder on the treatment page itself. Its blog walks the standard semaglutide climb of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, and the Zepbound page lists a 2.5 mg starting dose increased every four weeks up to 15 mg.
- Compounded semaglutide — $139 for the first month, then a 12-week charge averaging $199 a month
- Compounded tirzepatide — $179 for the first month, then a 12-week charge averaging $299 a month
- Brand-name Zepbound — a little above a thousand dollars a month for a 28-day supply, billed monthly at pharmacy cash rates; Wegovy, Ozempic and Mounjaro run higher
- No insurance routing on any of it — Pallas is cash-pay, with an itemized receipt for FSA or HSA claims
Pallas doesn't sell an oral or dissolving-tablet form of either GLP-1; it's injections only. It does sell NAD+, sermorelin, glutathione and women's hormone therapy from the same account, none of which this review covers.
What the intake asks — and where it stops you
“Start your visit” opens a four-stage flow labeled About you, Health, Your plan and Checkout. The first screens are light: your weight-loss goal in four ranges, a readiness question, whether you've taken a GLP-1 in the past month and which one, then height and weight with your BMI computed on the spot. The fifth screen asks for your date of birth, and from there the flow moves into personal details. So the plan-and-price step sits behind your identity, but the prices it shows are the same ones printed on the treatment page.
In 43 states the visit is fully asynchronous, with no video call. Seven states plus Washington, D.C. require one live video visit before a prescription: Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota and West Virginia. Refills are not automatic. The disclosures page says “each renewal involves clinician review of progress and tolerability.” The treatment page says “SHIPS IN ~1 WEEK,” and the brand pages say most orders arrive within about a week of approval. Pay-over-time is offered at checkout. Support is by message, a weekday phone line, or a free app that tracks doses and refills.
Trust and safety: an unusually complete disclosure page
Most cash-pay compounding sites tell you nothing about who prescribes or dispenses. Pallas publishes a clinical disclosures page, last updated June 2026, that names its clinical partner (Lion MD) and its clinical-operations platform (CareValidate). It lists two advising physicians with NPI numbers you can look up in the federal NPI database. It names six partner pharmacies with phone numbers: Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills. Pallas says it does this because Massachusetts, Rhode Island and Vermont rules require it. It accepts patients in all 50 states plus D.C. A LegitScript seal in the footer links to LegitScript's lookup tool, and there are no FDA warning letters against Pallas or its operator, Brentmoor, Inc.
A few things don't line up. The homepage claims “200,000+ patients” while the disclosures page describes a July 2026 launch and “existing waitlist patients.” The “4.8/5.0 from 2,400+ member reviews” badge doesn't link to where those reviews live. And the footer admits that “Some content on this site is AI-generated.” On the medication itself, Pallas is plain: compounded semaglutide and tirzepatide are not FDA-approved and are not generic versions of the brand-name drugs.
Who should choose it — and who should skip it
Choose Pallas if you want a flat price that includes the consult and shipping, you can budget for a three-month charge every 12 weeks, and you care about knowing which pharmacy and which clinicians are behind your order. The named pharmacies and the NPI numbers are a genuine advantage in this segment.
Skip it if you want month-to-month billing with a true monthly commitment; the standing plan is quarterly. Skip it if you want a refund window after your prescription is issued, because there isn't one outside the six-month promise. And skip it if you want an oral GLP-1 or a low-dose “microdose” line, which Pallas doesn't offer.
Bottom line
Pallas Health pairs an ordinary compounded price with an extraordinary amount of disclosure. The first-month rate is real, the flat-at-every-dose promise is written on the site, and the charge-only-when-prescribed checkout removes the usual risk of paying before a clinician looks at you. Go in knowing that the real bill is a 12-week charge, that it costs a bit more per year than the advertised average, and that once the prescription is written the money doesn't come back. For a cash-pay patient who wants to know exactly who is prescribing and dispensing, it earns a serious look. See how these factors are weighed in our scoring methodology.
Shopping around? Eden ($198/month) and Breeze Meds ($199/month) are the nearest alternatives to Pallas Health in our rankings.
The Bottom Line
Pallas Health scores highest on state availability and ease of access.
Ready to start with Pallas Health?
Starting at $139/month. See current pricing and start your free consultation.
Pallas Health might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
- If you want brand-name Ozempic, Wegovy, Mounjaro or Zepbound, consider GobyMeds.
- If the lowest possible monthly price is your top priority, consider Collective (from $59/mo).
- If you want built-in coaching and behavior-change support, consider Found.
Alternatives to Pallas Health
Sunlight
Best for: compounded GLP-1 with unlimited telehealth visits and free shipping
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Pallas Health review:
Sources & methodology — as of September 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Pallas Health's current pricing
Plans start at $139/month. Start your free consultation to check eligibility and today's price.